BCRX

#1835
BioCryst Pharmaceuticals Inc
9.67 USD
+2.65%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
9.67
9.67
Rango anual
6.00
11.31
Cambio diario
+2.65%
Variación mensual
+17.64%
Variación en los últimos 6 meses
+48.31%
Cambio anual
+38.34%
Cierres anteriores
9.42
Abrir
9.67
Bid
Ask
Mínimo
9.67
High
9.67
Volumen
103
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 2.43 B
  • Employee 435
  • Founded 1986
  • CEO Jon P. Stonehouse
  • Website www.biocryst.com
  • Headquarter Delaware, United States
  • FIGI BBG000BLYWX6
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
6.45
Relación precio/flujo de caja
1.95

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Noticias